Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 11 de 11
Filter
1.
Infect Genet Evol ; 37: 43-8, 2016 Jan.
Article in English | MEDLINE | ID: mdl-26518911

ABSTRACT

Individuals can be infected by either a single or multiple strains of Helicobacter pylori. Multiple infection with genetically different isolates and particularly mixed infection with both antibiotic-susceptible and resistant isolates are difficult to detect and should impact the effectiveness of eradication treatment. It is largely assumed that multiple infections are more frequent in developing countries but an actual comparison developing/developed using a single methodology has never been reported. To compare the prevalence of multiple and mixed H. pylori infection in Tunisia and France, we conducted a prospective study including 42 H. pylori-culture positive infected patients (21 Tunisian and 21 French) never previously treated for H. pylori infection. One gastric biopsy was collected from antrum. Three to eleven (mean = 9) colonies were isolated from each biopsy. A total of 375 different isolates were genotyped using RAPD fingerprinting and antimicrobial susceptibility testing was performed on amoxicillin, clarithromycin, ciprofloxacin, rifampicin, tetracycline and metronidazole with E-tests. Multiple infection was defined by different RAPD fingerprintings among the different isolates from a single patient. Mixed infection was defined by different resistance profiles among the different isolates from a single patient. Multiple H. pylori infection is more prevalent in Tunisia than in France. It occurred in ten (48%) Tunisian patients and in one (5%) French patient (p < 0.001). Mixed infection is common (24%), it occurred in 4 (19%) Tunisian patients and in 6 (29%) French patients (p = 0.46) and was mainly (8/10) due to genetically related clones in single infection.


Subject(s)
Anti-Bacterial Agents/pharmacology , Helicobacter Infections/epidemiology , Helicobacter pylori/classification , Helicobacter pylori/genetics , Adult , Aged , Aged, 80 and over , Drug Resistance, Bacterial , Female , France/epidemiology , Helicobacter Infections/microbiology , Helicobacter pylori/drug effects , Helicobacter pylori/isolation & purification , Humans , Male , Microbial Sensitivity Tests , Middle Aged , Prospective Studies , Pyloric Antrum/microbiology , Random Amplified Polymorphic DNA Technique , Tunisia/epidemiology
2.
J Biomol Struct Dyn ; 32(6): 866-75, 2014.
Article in English | MEDLINE | ID: mdl-24404772

ABSTRACT

The chemokine receptor 5 (CCR5) belongs to the superfamily of serpentine G protein-coupled receptors (GPCRs). The DRY motif (Asp, Arg, Tyr) of the intracellular loop 2 (ICL2), which is highly conserved in the GPCRs has been shown to be essential for the stability of folding of CCR5 and the interaction with ß-arrestin. But the molecular mechanism by which it recognizes and interacts with ß-arrestin has not been elucidated. In the present study, we described the active state of the ß-arrestin structure using normal mode analysis and characterized the binding cleft of CCR5-ICL2 with ß-arrestin using SABRE© docking tool and molecular dynamics simulation. Based on our computational results, we proposed a mode of binding between the ICL2 loop of CCR5 and ß-arrestin structure, and modeled the energetically stable ß-arrestin/CCR5 complex. In view of CCR5's importance as a therapeutic target for the treatment of HIV, this observation provides novel insight into the ß-arrestin/CCR5 pathway. As a result, the current computational study of the detailed ß-arrestin/CCR5 binding complex could provide the rationale for the development of next generation of HIV peptide inhibitors as therapeutic agents.


Subject(s)
Arrestins/chemistry , Receptors, CCR5/chemistry , Amino Acid Sequence , Binding Sites , Humans , Molecular Docking Simulation , Molecular Dynamics Simulation , Molecular Sequence Data , Protein Interaction Domains and Motifs , Protein Structure, Tertiary , Sequence Homology, Amino Acid , Thermodynamics , beta-Arrestins
3.
J Biomol Struct Dyn ; 32(8): 1202-10, 2014.
Article in English | MEDLINE | ID: mdl-23869485

ABSTRACT

We report the identification of a novel CC chemokine receptor 5 (CCR5) variant that seems associated with resistance to HIV-1 infection. The V130I mutation of the CCR5 receptor is located in the intracellular loop ICL2 known as DRY box and described in the literature as a nonsynonymous mutation present in nonhuman primates group. Extensive molecular modeling and dynamics simulations were performed to elucidate the mechanism by which the V130I mutation may induce conformational change of the CCR5 folding protein and prevent the interaction with the ß-arrestin protein. Our study provides new mechanistic insight into how a specific mutation in the regulatory domain of CCR5 might alter the structural folding of the DRY box and the possible ICL2 loop binding with the ß-arrestin protein, as described in our previous computational study. The results from our large-scale simulations complement recent experimental results and clinical features and offer useful insights into the mechanism behind CCR5 protein folding and signal transduction. In order for HIV, the entry of the virus to the cells must fuse with the CCR5 receptor that sits on the surface of T-helper immune cells. The described V130I mutation in the gene encoding the CCR5 protein may results in a defective CCR5-Arrestin binding complex that blocks entry of the virus.


Subject(s)
HIV Infections/virology , HIV-1/genetics , Receptors, CCR5/chemistry , Amino Acid Sequence , Arrestins/chemistry , Disease Resistance , HIV Infections/genetics , HIV-1/metabolism , Humans , Molecular Dynamics Simulation , Molecular Sequence Data , Mutation , Protein Binding , Protein Folding , Receptors, CCR5/genetics , beta-Arrestins
4.
Diagn Pathol ; 7: 138, 2012 Oct 08.
Article in English | MEDLINE | ID: mdl-23044036

ABSTRACT

In this study we report the prevalence of antiretroviral drug resistant HIV-1 genotypes of virus isolated from Djiboutian patients who failed first-line antiretroviral therapy (ART) and from ART naïve patients. PATIENTS AND METHODS: A total of 35 blood samples from 16 patients who showed first-line ART failure (>1000 viral genome copies/ml) and 19 ART-naïve patients were collected in Djibouti from October 2009 to December 2009. Both the protease (PR) and reverse transcriptase (RT) genes were amplified and sequenced using National Agency for AIDS Research (ANRS) protocols. The Stanford HIV database algorithm was used for interpretation of resistance data and genotyping. RESULTS: Among the 16 patients with first-line ART failure, nine (56.2%) showed reverse transcriptase inhibitor-resistant HIV-1 strains: two (12.5%) were resistant to nucleoside (NRTI), one (6.25%) to non-nucleoside (NNRTI) reverse transcriptase inhibitors, and six (37.5%) to both. Analysis of the DNA sequencing data indicated that the most common mutations conferring drug resistance were M184V (38%) for NRTI and K103N (25%) for NNRTI. Only NRTI primary mutations K101Q, K103N and the PI minor mutation L10V were found in ART naïve individuals. No protease inhibitor resistant strains were detected. In our study, we found no detectable resistance in ∼ 44% of all patients who experienced therapeutic failure which was explained by low compliance, co-infection with tuberculosis and malnutrition. Genotyping revealed that 65.7% of samples were infected with subtype C, 20% with CRF02_AG, 8.5% with B, 2.9% with CRF02_AG/C and 2.9% with K/C. CONCLUSION: The results of this first study about drug resistance mutations in first-line ART failures show the importance of performing drug resistance mutation test which guides the choice of a second-line regimen. This will improve the management of HIV-infected Djiboutian patients. VIRTUAL SLIDES: The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/2051206212753973.


Subject(s)
Anti-Retroviral Agents/therapeutic use , Drug Resistance, Viral/genetics , HIV Infections/drug therapy , HIV Protease/genetics , HIV Reverse Transcriptase/genetics , HIV-1/drug effects , Adult , CD4 Lymphocyte Count , Coinfection , Comorbidity , DNA Mutational Analysis , Djibouti/epidemiology , Female , Genotype , HIV Infections/diagnosis , HIV Infections/virology , HIV-1/genetics , HIV-1/pathogenicity , Humans , Male , Malnutrition/epidemiology , Medication Adherence , Microbial Sensitivity Tests , Mutation , Risk Assessment , Risk Factors , Treatment Failure , Tuberculosis/epidemiology
5.
Diagn Pathol ; 7: 93, 2012 Aug 10.
Article in English | MEDLINE | ID: mdl-22883072

ABSTRACT

INTRODUCTION: Hemophilia A is an X linked recessive hemorrhagic disorder caused by mutations in the F8 gene that lead to qualitative and/or quantitative deficiencies of coagulation factor VIII (FVIII). Molecular diagnosis of hemophilia A is challenging because of the high number of different causative mutations that are distributed throughout the large F8 gene. Molecular studies of these mutations are essential in order to reinforce our understanding of their pathogenic effect responsible for the disorder. AIM: In this study we have performed molecular analysis of 28 Tunisian hemophilia A patients and analyzed the F8 mutation spectrum. METHODS: We screened the presence of intron 22 and intron 1 inversion in severe hemophilia A patients by southern blotting and polymerase chain reaction (PCR). Detection of point mutations was performed by dHPLC/sequencing of the coding F8 gene region. We predict the potential functional consequences of novel missense mutations with bioinformatics approaches and mapping of their spatial positions on the available FVIII 3D structure. RESULTS: We identified 23 different mutations in 28 Tunisian hemophilia A patients belonging to 22 unrelated families. The identified mutations included 5 intron 22 inversions, 7 insertions, 4 deletions and 7 substitutions. In total 18 point mutations were identified, of which 9 are located in exon 14, the most mutated exonic sequence in the F8 gene. Among the 23 mutations, 8 are novel and not deposited in the HAMSTeRS database nor described in recently published articles. CONCLUSION: The mutation spectrum of Tunisian hemophilia A patients is heterogeneous with the presence of some characteristic features. VIRTUAL SLIDES: The virtual slide(s) for this article can be found here:http://www.diagnosticpathology.diagnomx.eu/vs/1693269827490715.


Subject(s)
Factor VIII/genetics , Hemophilia A/genetics , Mutation , Adolescent , Adult , Blotting, Southern , Child , Child, Preschool , Computational Biology , DNA Mutational Analysis , Databases, Genetic , Exons , Factor VIII/chemistry , Genetic Predisposition to Disease , Hemophilia A/blood , Hemophilia A/diagnosis , Humans , Introns , Models, Molecular , Mutagenesis, Insertional , Mutation, Missense , Phenotype , Point Mutation , Polymerase Chain Reaction , Protein Conformation , Sequence Deletion , Sequence Inversion , Severity of Illness Index , Structure-Activity Relationship , Tunisia/epidemiology , Young Adult
6.
Diagn Pathol ; 7: 92, 2012 Aug 08.
Article in English | MEDLINE | ID: mdl-22873696

ABSTRACT

Inherited factor VII (FVII) deficiency is a rare disorder characterized by a bleeding phenotype varying from mild to severe. To date, more than 200 mutations have been described along the F7 gene encoding for FVII. The aim of this study was the identification of genetic defects underlying FVII deficiency in 10 patients belonging to eight unrelated families of the North provinces from Tunisia. Mutation detection was performed by sequencing the whole F7 gene coding region, exon-intron boundaries and about 400 bp of the promoter region. We identified 5 mutations in five unrelated families; the novel p.F328Y mutation and the reported mutations: p.R304Q, p.M298I, IVS1aG > A and p.G-39G. For the remaining 5 patients we didn't identified any mutations using PCR/Sequencing protocol. In conclusion, this study represents the first comprehensive molecular series of FVII deficiency affected patients in Tunisia from the North. We will try in the future to continue the molecular study for Tunisian patients from Center and South provinces in order to have a complete idea about the FVII deficiency mutational profile in our country. VIRTUAL SLIDES: The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/1288044089753085.


Subject(s)
Blood Coagulation/genetics , Factor VII Deficiency/genetics , Factor VII/genetics , Mutation , Polymorphism, Single Nucleotide , Adolescent , Adult , Blood Coagulation/drug effects , Blood Coagulation Factors/therapeutic use , Coagulants/therapeutic use , Contusions/blood , Contusions/genetics , DNA Mutational Analysis , Epistaxis/blood , Epistaxis/genetics , Exons , Factor VII Deficiency/blood , Factor VII Deficiency/drug therapy , Factor VII Deficiency/epidemiology , Female , Genetic Predisposition to Disease , Humans , Introns , Male , Menorrhagia/blood , Menorrhagia/genetics , Metrorrhagia/blood , Metrorrhagia/genetics , Middle Aged , Phenotype , Promoter Regions, Genetic , Tunisia/epidemiology , Young Adult
7.
Diagn Pathol ; 6: 54, 2011 Jun 17.
Article in English | MEDLINE | ID: mdl-21682900

ABSTRACT

BACKGROUND: The development of inhibitors against factor 8 (F8) is the most serious complication of replacement therapy with F8 in children with severe hemophilia. It was suggested that mismatched F8 replacement therapy may be a risk factor for the development of anti-factor F8 alloantibodies. Recently four single nucleotide polymorphisms (SNPs) encoding six distinct haplotypes, designated H1 through H6, were studied in different populations. Two SNPs are components of the A2 and C2 immunodominant-inhibitor epitopes.The aim of this study is to determine the different types of haplotypes in relation with inhibitors developments and their frequencies in our Tunisian hemophiliac population. MATERIALS AND METHODS: 95/116 Tunisian patients with hemophilia A undergoing treatment at Hemophilia Treatment Center, Aziza Othmana hospital, participate in this study. Among them only six patients develop inhibitors. The four SNPs were amplified and sequenced. RESULTS AND DISCUSSION: In a total of 77 patients, we identified the H1, H2, H3 and the infrequent H5 haplotypes. The H1 and H2 haplotypes, which have the same amino acid sequence in the recombinant F8 molecules used clinically, are the most represented with the frequency of 0.763 and 0.157 respectively. This distribution is almost similar to that of Caucasians in which the frequencies are respectively 0.926 and 0.074, whereas it is 0.354 and 0.374 among Subsaharians. Four patients with inhibitors studied here have the H1 haplotype. For one patient who has a large deletion including the exon 10 we can't identify his haplotype. Theses frequencies may explain partially the low level of inhibitors in our patients.


Subject(s)
Factor VIII/genetics , Hemophilia A/genetics , Immunodominant Epitopes/genetics , Polymorphism, Single Nucleotide , Coagulants/therapeutic use , Factor VIII/immunology , Factor VIII/therapeutic use , Gene Frequency , Genetic Predisposition to Disease , Haplotypes , Hemophilia A/drug therapy , Hemophilia A/epidemiology , Hemophilia A/immunology , Humans , Isoantibodies/blood , Phenotype , Tunisia/epidemiology
9.
Tunis Med ; 86(6): 534-9, 2008 Jun.
Article in French | MEDLINE | ID: mdl-19216443

ABSTRACT

OBJECTIVE: Our aim is to determine different therapeutic response profiles in Tunisian HIV-1 infected patients, to identify those with therapeutic failure and to compare the results of the genotypic resistance test used in Tunisia (INNO LiPA Test) with those of automatic sequencing to evaluate its efficacy. METHODS: The retrospective survey concerns 392 infected patients enrolled from January 2001 to December 2006. Evaluation of HIV INNO LiPA test was performed by comparing these test results with those of automatic sequencing in 36 plasmatic samples for 13 infected patients with therapeutic failure. RESULTS: on the basis of the HIV viral load evolution, 57.55% of patients present a good therapeutic response and 42.44% a bad one. Patients with therapeutic failure require genotypic resistance test. A comparison of HIV INNO LiPA test and direct sequencing showed a strong concordance between the two tests results either for reverse transcriptase gene or protease gene. However, the results obtained by INNO LiPA test (8.79% of analysed codons ) and the limited number of analysed codons were the defaults of INNO LiPA technique. CONCLUSION: the contribution of INNO LiPA technique in the knowledge of the epidemiological HIV resistance profiles of virus strains of HIV infected individuals failing therapy was considerable. However, due to INNO LiPA technique limitations, sequence analysis must be considered a more complete assay for the monitoring of antiretroviral resistance of HIV infected patients.


Subject(s)
Anti-HIV Agents/pharmacology , HIV Infections/drug therapy , HIV-1/drug effects , Adult , Anti-HIV Agents/therapeutic use , Antiretroviral Therapy, Highly Active , Drug Resistance, Viral/genetics , Female , Genotype , HIV Infections/virology , HIV-1/genetics , Humans , Male , Reagent Kits, Diagnostic , Retrospective Studies , Reverse Transcriptase Polymerase Chain Reaction , Treatment Failure , Treatment Outcome , Tunisia , Viral Load
10.
Hum Immunol ; 68(12): 993-1000, 2007 Dec.
Article in English | MEDLINE | ID: mdl-18191728

ABSTRACT

Polymorphisms in some chemokine receptor genes are associated with susceptibility to and progression of human immunodeficiency virus-1 (HIV-1) infection. Most mutations detected in the CC-chemokine receptor 5 (CCR5) gene are specific to different populations. In this study, we focused on polymorphisms of the CCR5 coding region in three healthy populations from Tunisia, corresponding to a cosmopolitan population from Tunis, and two isolated Berber populations. In addition to the CCR5-Delta32 deletion, eleven single nucleotide polymorphisms were detected. Some of these point mutations were associated with the same genotype and even the same haplotype. The (L55Q-C101X), I124, V131F, T143N, A159V, I237, T239A and G301R alleles have not been described previously, whereas the CCR5-Delta32, L55Q, A335V and Y339F variants have already been reported in the literature. The distribution and frequency of these variants were different among the three groups studied, a result in agreement with the mosaic genetic structure of the Tunisian population. To determine whether these alleles affect HIV-1 transmission, we compared allele frequencies between healthy and HIV-1 infected individuals from Tunis. The frequency of the CCR5-Delta32 variant was significantly different between the two groups, leading us to conclude that this mutation might confer protection against HIV infection in Tunisian populations.


Subject(s)
HIV Infections/genetics , HIV-1 , Immunity, Innate/genetics , Mutation , Receptors, CCR5/genetics , Adult , Alleles , Female , Gene Frequency , Genotype , HIV Infections/immunology , HIV Infections/transmission , HIV Infections/virology , Haplotypes , Humans , Male , Polymorphism, Genetic , Tunisia
SELECTION OF CITATIONS
SEARCH DETAIL
...